APA (7th ed.) Citation

Radigan, R., Sangal, A., Zhang, D., Weber, J., Schmalzle, M., Finkelstein, A., . . . Kao, J. (2025). Feasibility trial of Darwin OncoTreat and OncoTarget precision medicine testing to improve outcomes for patients with limited metastatic disease that failed first-line systemic therapy. PLoS ONE, 20(6), 1. https://doi.org/10.1371/journal.pone.0325769

Chicago Style (17th ed.) Citation

Radigan, Rachel, Ashish Sangal, Dong Zhang, Jonathan Weber, Megha Schmalzle, Alexa Finkelstein, Vaibhav Duggal, and Johnny Kao. "Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing to Improve Outcomes for Patients with Limited Metastatic Disease That Failed First-line Systemic Therapy." PLoS ONE 20, no. 6 (2025): 1. https://doi.org/10.1371/journal.pone.0325769.

MLA (9th ed.) Citation

Radigan, Rachel, et al. "Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing to Improve Outcomes for Patients with Limited Metastatic Disease That Failed First-line Systemic Therapy." PLoS ONE, vol. 20, no. 6, 2025, p. 1, https://doi.org/10.1371/journal.pone.0325769.